# lymphoma (blogs) — RSS Amplifier Recent posts from the 1 feeds in the RSS Amplifier directory that cover lymphoma. Page: Feed: --- ## [Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL](https://sohoinsider.com/news/liso-cel-ibrutinib-remissions-relapsed-refractory-cll-sll/?utm_source=rss&utm_medium=rss&utm_campaign=liso-cel-ibrutinib-remissions-relapsed-refractory-cll-sll) _2026-08-21 · Kerri Fitzgerald · SOHO Insider_ William G. Wierda, MD, of the University of Texas MD Anderson Cancer Center, and colleagues, published the findings in Blood. The post Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL appeared first on SOHO Insider . ## [Partnership expands access to CLL treatment in low-, middle-income countries](https://sohoinsider.com/news/partnership-expands-access-to-cll-treatment-in-low-middle-income-countries/?utm_source=rss&utm_medium=rss&utm_campaign=partnership-expands-access-to-cll-treatment-in-low-middle-income-countries) _2026-08-20 · SOHO Insider Editors · SOHO Insider_ To date, the initiative has enabled access to the treatment for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding its original scope by about 150 patients. The post Partnership expands access to CLL treatment in low-, middle-income countries appeared first on SOHO Insider . ## [Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN](https://sohoinsider.com/leukemia/phase-1-data-reported-for-anti-cd123-car-t-cell-therapy-in-relapsed-or-refractory-aml-bpdcn/?utm_source=rss&utm_medium=rss&utm_campaign=phase-1-data-reported-for-anti-cd123-car-t-cell-therapy-in-relapsed-or-refractory-aml-bpdcn) _2026-08-19 · Patrick Daly · SOHO Insider_ The study’s authors, led by Lihua E Budde, MD, PhD, of City of Hope in Duarte, California, published the findings in the Journal of Hematology & Oncology. The post Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN appeared first on SOHO Insider . ## [Drs. George Lenz and Loretta Nastoupil discuss phase 3 FRONTMIND study](https://sohoinsider.com/lymphoma/drs-george-lenz-and-loretta-nastoupil-discuss-phase-3-frontmind-study/?utm_source=rss&utm_medium=rss&utm_campaign=drs-george-lenz-and-loretta-nastoupil-discuss-phase-3-frontmind-study) _2026-08-18 · Leah Sherwood · SOHO Insider_ From EHA 2026, Dr. Loretta Nastoupil interviews Dr. Georg Lenz on the phase 3 FRONTMIND study, a randomised, double-blind, placebo-controlled study that evaluated tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma. The post Drs. George Lenz and Loretta Nastoupil discuss phase 3 FRONTMIND study appeared first on… ## [FDA grants accelerated approval to iberdomide combo in multiple myeloma](https://sohoinsider.com/news/fda-grants-accelerated-approval-to-iberdomide-combo-in-multiple-myeloma/?utm_source=rss&utm_medium=rss&utm_campaign=fda-grants-accelerated-approval-to-iberdomide-combo-in-multiple-myeloma) _2026-08-14 · SOHO Insider Editors · SOHO Insider_ ...the approval is based on results from the Phase 3 EXCALIBER-RRMM trial, which showed iberdomide significantly improved minimal residual disease (MRD)-negative complete response (CR) rates. The post FDA grants accelerated approval to iberdomide combo in multiple myeloma appeared first on SOHO Insider . ## [Post-transplantation outcomes have improved for Hodgkin lymphoma](https://sohoinsider.com/lymphoma/post-transplantation-outcomes-have-improved-for-hodgkin-lymphoma/?utm_source=rss&utm_medium=rss&utm_campaign=post-transplantation-outcomes-have-improved-for-hodgkin-lymphoma) _2026-08-14 · Leah Sherwood · SOHO Insider_ The improved post-transplantation outcomes are likely due to the introduction of novel therapeutic agents, alongside advances in donor selection, conditioning regimens, and graft-versus-host disease prophylaxis, the authors suggested. The post Post-transplantation outcomes have improved for Hodgkin lymphoma appeared first on SOHO Insider . ## [Fedratinib demonstrates favorable OS in MDS/MPN overlap syndrome](https://sohoinsider.com/myeloproliferative-neoplasms/fedratinib-demonstrates-favorable-os-in-mds-mpn-overlap-syndrome/?utm_source=rss&utm_medium=rss&utm_campaign=fedratinib-demonstrates-favorable-os-in-mds-mpn-overlap-syndrome) _2026-08-11 · SOHO Insider Editors · SOHO Insider_ The results showed a 30% spleen response rate and a 47% symptom response rate among evaluable patients. Overall survival reached around 37 months, which compares favorably to historical controls where survival is typically between one and three years. The post Fedratinib demonstrates favorable OS in MDS/MPN overlap syndrome appeared first on SOHO Insider . ## [NICE recommends acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukemia](https://sohoinsider.com/news/nice-recommends-acalabrutinib-for-mantle-cell-lymphoma-chronic-lymphocytic-leukemia/?utm_source=rss&utm_medium=rss&utm_campaign=nice-recommends-acalabrutinib-for-mantle-cell-lymphoma-chronic-lymphocytic-leukemia) _2026-08-11 · SOHO Insider Editors · SOHO Insider_ The draft guidance expands frontline options for patients who are ineligible for stem cell transplants or who require oral therapies. The post NICE recommends acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukemia appeared first on SOHO Insider . ## [FDA approves subcutaneous isatuximab-irfc for multiple myeloma](https://sohoinsider.com/news/fda-approves-subcutaneous-isatuximab-irfc-for-multiple-myeloma/?utm_source=rss&utm_medium=rss&utm_campaign=fda-approves-subcutaneous-isatuximab-irfc-for-multiple-myeloma) _2026-08-11 · SOHO Insider Editors · SOHO Insider_ Isatuximab-irfc is currently approved across three indications in the US, including in combination with bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant, Sanofi reported in the release. The post FDA approves subcutaneous isatuximab-irfc for multiple myeloma appeared first on SOHO Insider . ## [ASCO and EHA 2026 updates on the third-gen TKI olverembatinib](https://sohoinsider.com/leukemia/asco-and-eha-2026-updates-on-the-third-gen-tki-olverembatinib/?utm_source=rss&utm_medium=rss&utm_campaign=asco-and-eha-2026-updates-on-the-third-gen-tki-olverembatinib) _2026-08-11 · SOHO Insider Editors · SOHO Insider_ Dr. Jabbour details safety and efficacy findings for an olverembatinib plus blinatumomab combination in leukemia. The post ASCO and EHA 2026 updates on the third-gen TKI olverembatinib appeared first on SOHO Insider . ## [Ship everywhere from one CLI (Sponsored)](https://crawlproof.com/a/P7muCUxvtpVO) _2026-08-11 · **Sponsored**_ One codebase, hosted runners, encrypted credentials, and automated submissions across stores ## [Global KMT2A MRD testing launched for AML,ALL](https://sohoinsider.com/news/global-kmt2a-mrd-testing-launched-for-aml-all/?utm_source=rss&utm_medium=rss&utm_campaign=global-kmt2a-mrd-testing-launched-for-aml-all) _2026-08-10 · SOHO Insider Editors · SOHO Insider_ The standardized assay targets common KMT2A partner fusion genes to support disease characterization and longitudinal monitoring in menin inhibitor clinical trials. The post Global KMT2A MRD testing launched for AML,ALL appeared first on SOHO Insider .